Evidence map›Paper›PMID 25915526›Full record

ArticlePloS one2015

Phosphorylation of transcription factor specificity protein 4 is increased in peripheral blood mononuclear cells of first-episode psychosis.

Raquel Pinacho, Gregory Saia, Montserrat Fusté, Iria Meléndez-Pérez, Victoria Villalta-Gil, Josep Maria Haro, Grace Gill, Belén Ramos

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Raquel PinachoUnitat de recerca, Fundació Sant Joan de Déu, Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Sant Boi de Llobregat, Barcelona, Spain.
Gregory SaiaDepartment of Developmental, Molecular, and Chemical Biology, Tufts University School of Medicine, Boston, Massachusetts, United States of America; Cell, Molecular and Developmental Biology Program, Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States of America.
Montserrat FustéUnitat de recerca, Fundació Sant Joan de Déu, Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Sant Boi de Llobregat, Barcelona, Spain.
Iria Meléndez-PérezUnitat de recerca, Fundació Sant Joan de Déu, Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Sant Boi de Llobregat, Barcelona, Spain.
Victoria Villalta-GilUnitat de recerca, Fundació Sant Joan de Déu, Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Sant Boi de Llobregat, Barcelona, Spain.
Josep Maria HaroUnitat de recerca, Fundació Sant Joan de Déu, Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Sant Boi de Llobregat, Barcelona, Spain.
Grace GillDepartment of Developmental, Molecular, and Chemical Biology, Tufts University School of Medicine, Boston, Massachusetts, United States of America.
Belén RamosUnitat de recerca, Fundació Sant Joan de Déu, Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Sant Boi de Llobregat, Barcelona, Spain.
Universitat de Barcelona · ESParc Sanitari Sant Joan de Déu · ESTufts University · US

Funding

Mechanisms of Neuronal Specific TranscriptionR01HD043364 · NICHD · TUFTS UNIVERSITY BOSTON · PI GILL, GRACE B · 2003 to 2009
$1.9M
Synapse Neurobiology Training ProgramT32NS061764 · NINDS · TUFTS UNIVERSITY BOSTON · PI BIEDERER, THOMAS · 2009 to 2019
$1.7M
NICHD NIH HHS R01 HD043364NINDS NIH HHS T32 NS061764
6 · The paper itself

Abstract

backgroundAltered expression of transcription factor specificity protein 4 (SP4) has been found in the postmortem brain of patients with psychiatric disorders including schizophrenia and bipolar disorder. Reduced levels of SP4 protein have recently been reported in peripheral blood mononuclear cells in first-episode psychosis. Also, SP4 levels are modulated by lithium treatment in cultured neurons. Phosphorylation of SP4 at S770 is increased in the cerebellum of bipolar disorder subjects and upon inhibition of NMDA receptor signaling in cultured neurons. The aim of this study was to investigate whether SP4 S770 phosphorylation is increased in lymphocytes of first-episode psychosis patients and the effect of lithium treatment on this phosphorylation.

methodsA cross-sectional study of S770 phosphorylation relative to total SP4 immunoreactivity using specific antibodies in peripheral blood mononuclear cells in first-episode psychosis patients (n = 14, treated with lithium or not) and matched healthy controls (n = 14) by immunoblot was designed. We also determined the effects of the prescribed drugs lithium, olanzapine or valproic acid on SP4 phosphorylation in rat primary cultured cerebellar granule neurons.

resultsWe found that SP4 S770 phosphorylation was significantly increased in lymphocytes in first-episode psychosis compared to controls and decreased in patients treated with lithium compared to patients who did not receive lithium. Moreover, incubation with lithium but not olanzapine or valproic acid reduced SP4 phosphorylation in rat cultured cerebellar granule neurons.

conclusionsThe findings presented here indicate that SP4 S770 phosphorylation is increased in lymphocytes in first-episode psychosis which may be reduced by lithium treatment in patients. Moreover, our study shows lithium treatment prevents this phosphorylation in vitro in neurons. This pilot study suggests that S770 SP4 phosphorylation could be a peripheral biomarker of psychosis, and may be regulated by lithium treatment in first-episode psychosis.

Indexed as

AdolescentAdultAnimalsAntipsychotic AgentsBenzodiazepinesCells, CulturedCross-Sectional StudiesFemaleHumansLithiumMaleModels, BiologicalNeuronsOlanzapinePhosphorylationPilot ProjectsAntipsychotic AgentsBenzodiazepinesLithiumOlanzapineSerineSP4 protein, humanSp4 Transcription FactorValproic Acid

Identifiers

PMID25915526
PMCPMC4411105
OpenAlexW2050664467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.